000			03358nam a22005657a 4500
008			150313s20142014 xxu||||| |||| 00| 0 eng d
022			_a0896-4327
040			_aOvid MEDLINE(R)
099			_a24028183
245			_aSecond-generation everolimus-eluting stents compared to first-generation drug-eluting stents in patients treated for multivessel disease.
251			_aJournal of Interventional Cardiology. 26(6):561-9, 2013 Dec.
252			_aJ. INTERVENT. CARDIOL.. 26(6):561-9, 2013 Dec.
253			_aJournal of interventional cardiology
260			_c2013
260			_fFY2014
266			_d2015-03-17
520			_aBACKGROUND: Second-generation EES have demonstrated superiority over first-generation DES for single-vessel disease, although the merits of EES in MVD are less established.
520			_aCONCLUSIONS: The use of EES in patients with MVD is safe with signals for improved effectiveness compared to first-generation DES. Randomized trials comparing new-generation DES to coronary artery bypass grafting surgery are warranted.Copyright � 2013, Wiley Periodicals, Inc.
520			_aMETHODS: A cohort of 1, 285 patients (3, 124 lesions) with > 2 diseased vessels were treated with either first-generation DES (n=1, 002) or EES (n=283). The rates of death, myocardial infarction, target lesion revascularization, target vessel revascularization, definite stent thrombosis, and major adverse cardiac events (MACE), defined as the combined incidence of target vessel revascularization, death, and non-fatal myocardial infarction, were compared at 1 year.
520			_aOBJECTIVE: This study aimed to compare the safety and efficacy of everolimus-eluting stents (EES) to first-generation drug-eluting stents (DES) in multivessel disease (MVD).
520			_aRESULTS: Baseline characteristics were similar except for a lower left ventricular ejection fraction and a lower incidence of stable angina pectoris in the first-generation DES group (P=0.001 and 0.013, respectively). At 1 year, the MACE rate was lower in the EES group (9.5P% vs. 15.7%; P=0.01). Multivariable analysis demonstrated that EES use predicted a higher chance of freedom from MACE at 1 year (hazard ratio 0.58 [0.38-0.87]; P=0.009; 95% confidence interval).
546			_aEnglish
650			_a*Coronary Disease/th [Therapy]
650			_a*Drug-Eluting Stents
650			_a*Sirolimus/aa [Analogs & Derivatives]
650			_aAged
650			_aCoronary Angiography
650			_aCoronary Disease/co [Complications]
650			_aFemale
650			_aHumans
650			_aMale
650			_aSirolimus/ad [Administration & Dosage]
650			_aTreatment Outcome
651			_aMedStar Heart & Vascular Institute
657			_aComparative Study
657			_aJournal Article
700			_aBadr, Salem
700			_aBarbash, Israel M
700			_aDvir, Danny
700			_aKitabata, Hironori
700			_aLoh, Joshua P
700			_aMinha, Sa'ar
700			_aPendyala, Lakshmana K
700			_aPichard, Augusto D
700			_aTorguson, Rebecca
700			_aWaksman, Ron
790			_aBadr S, Barbash IM, Dvir D, Kitabata H, Loh JP, Minha S, Pendyala LK, Pichard AD, Torguson R, Waksman R
856			_uhttp://dx.doi.org/10.1111/joic.12063 _zhttp://dx.doi.org/10.1111/joic.12063
942			_cART _dArticle
999			_c1076 _d1076